CUAMC
RXRX icon

China Universal Asset Management Company’s Recursion Pharmaceuticals RXRX Stock Holding History

China Universal Asset Management Company’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Sell
83,503
-9,121
-10% -$30.4K 0.02% 319
2026
Q1 		$284K Buy
92,624
+8,837
+11% +$34.1K 0.02% 321
2025
Q4 		$343K Buy
83,787
+8,885
+12% +$44K 0.03% 289
2025
Q3 		$366K Sell
74,902
-5,367
-7% -$28.2K 0.03% 278
2025
Q2 		$406K Buy
80,269
+1,024
+1% +$5.03K 0.04% 257
2025
Q1 		$419K Sell
79,245
-1,698
-2% -$12.4K 0.04% 260
2024
Q4 		$547K Buy
80,943
+28,038
+53% +$189K 0.05% 242
2024
Q3 		$349K Buy
52,905
+25,851
+96% +$185K 0.04% 255
2024
Q2 		$203K Sell
27,054
-16,602
-38% -$145K 0.03% 243
2024
Q1 		$435K Buy
43,656
+19,565
+81% +$218K 0.06% 196
2023
Q4 		$238K Buy
24,091
+18,854
+360% +$134K 0.05% 191
2023
Q3 		$40.1K Buy
5,237
+2,817
+116% +$28.1K 0.01% 242
2023
Q2 		$18.1K Sell
2,420
-65
-3% -$455 0.01% 278
2023
Q1 		$16.6K Buy
2,485
+639
+35% +$5.07K 0.01% 240
2022
Q4 		$14.2K Buy
1,846
+299
+19% +$2.93K 0.01% 199
2022
Q3 		$16K Buy
+1,547
New +$15.7K 0.01% 168

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

China Universal Asset Management Company's RXRX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Recursion Pharmaceuticals (RXRX) stake by 9.8% in Q2 2026, selling an estimated $30.4K and leaving 83,503 shares worth $306K. The position accounts for 0.02% of the portfolio, ranked #319.

China Universal Asset Management Company first reported a position in RXRX in Q3 2022 and has held it in 16 quarters since. The position peaked at $547K in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • China Universal Asset Management Company held 83,503 shares of Recursion Pharmaceuticals worth $306K as of Q2 2026.
  • China Universal Asset Management Company sold 9,121 Recursion Pharmaceuticals shares in Q2 2026, an estimated $30.4K.
  • Recursion Pharmaceuticals made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #319 holding.
  • China Universal Asset Management Company first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Recursion Pharmaceuticals position peaked at $547K in Q4 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.